RNA interference (RNAi) was first literaturally reported in 1998 and has become rapidly a
promising tool for therapeutic applications in gene therapy. In a typical RNAi process, small …

There is a tremendous interest in moving siRNA therapeutics into a clinical setting for the
treatment of various diseases. This in itself however depends largely on the availability of …

Over the last decades, gene therapy has emerged as a pioneering therapeutic approach to
treat or prevent several diseases. Among the explored strategies, the short-term silencing of …

siRNA technology presents a helpful means of gene silencing in mammalian cells.
Advancement in the field includes enhanced attentiveness in the characterization of target …

Background: Therapeutic efficacy of dreadful diseases like cancer, HIV (Human
Immunodeficiency Virus) can be enhanced by delivering molecules which regulate function …

Since the discovery of the “starburst polymer”, later renamed as dendrimer, this class of
polymers has gained considerable attention for numerous biomedical applications, due …

Small interfering RNA (siRNA) therapeutics hold great promise to treat a variety of diseases,
as long as they can be delivered safely and effectively into cells. Dendrimers are appealing …

Purpose Delivery of siRNA into cells remains a critical challenge. Our lab has shown a novel
polyamidoamine (PAMAM) dendrimer with modified pentaerythritol derivative core (PD …

A neutral cross-linked dendritic system is described for use of delivering small interfering
RNA (siRNA) for targeted gene silencing. By replacing the terminal amines with hydrazide …

Gene therapy using small interfering RNA (siRNA) is emerging as a novel therapeutic
approach to treat various diseases. However, safe and efficient siRNA delivery still …